Drug Industry – Talk Bio

Trump Administration Weighs Severe Restrictions on US Pharmas Licensing Chinese Medicines

1 week ago talkbio0Tagged AstraZeneca, chinese medicine, Drug Industry, drug manufacturing, executive order, licensing restrictions, lobbying, National Security, Pfizer, Transplant Registry Unified Management Program, United States Food and Drug Administration

Trump administration; Chinese medicines; executive order; pharmaceutical industry; licensing restrictions; national security; lobbying; Pfizer; AstraZeneca; biotech; drug manufacturing; FDA review

AstraZeneca Ends Manufacturing License at Indian Plant and Exits Site as Part of Global Strategy

2 weeks ago talkbio0Tagged AstraZeneca, Bangalore plant, Contract agreement, Drug Industry, global strategy, India, Manufacturing, manufacturing license, Site of exit

AstraZeneca; India; manufacturing license; site exit; Bangalore plant; contract manufacturing; global strategy; pharmaceutical industry

UK Drugmakers and Government at Impasse Over New Medicine Rebate Scheme

3 weeks ago talkbio0Tagged Drug Industry, drugmakers, Government, Health Services, National, Mediation, rates, statutory scheme, UK, valproic acid glucuronide

UK; drugmakers; medicine rebate; government negotiations; VPAG; statutory scheme; pharmaceutical industry; National Health Service; rebate rates

Draft MAHA Commission Report Outlines Broad Vaccine Framework and Addresses Childhood Chronic Disease

4 weeks ago talkbio0Tagged CDC, Centers for Disease Control and Prevention (U.S.), childhood vaccine schedule, Chronic disease, Commission, draft report, Drug Industry, MAHA, medical freedom, overmedicalization, vaccine framework, vaccine injuries

MAHA Commission; draft report; vaccine framework; childhood vaccine schedule; vaccine injuries; medical freedom; conflicts of interest; CDC; chronic disease; overmedicalization; pharmaceutical industry

Tariffs and MFN Policy Power a Broad, Confusing Pharma War

4 weeks ago talkbio0Tagged Drug Industry, drug manufacturing, Drug Prescriptions, Medicaid, MFN, Nation, onshoring, pharma innovation, Policy, Trump administration

tariffs; Most Favored Nation (MFN) policy; prescription drug pricing; pharmaceutical industry; Trump administration; drug manufacturing; onshoring; Medicaid; pharma innovation

Amid MFN Talks, Lilly Chief Warns US Adoption of International Drug Prices Could Bring ‘Worst of Two Worlds’

1 month ago talkbio0Tagged Cautionary Warning, Chief, Does speak, Drug Industry, drug price, Eli Lilly, International Drug Prices, MFN, Policy, U.S.

Lilly chief; MFN talks; international drug prices; US drug pricing; pharmaceutical industry; policy warning

Pfizer CEO Holds ‘Extremely Productive’ Talks With Trump Administration Amid MFN Pricing and Tariff Threats

1 month ago talkbio0Tagged Albert Bourla, Direct-to-Consumer, Drug Industry, drug price, Jr., Mehmet, Nation, negotiation, ounce, Pfizer, PhRMA, Policy, Pricing, Robert F. Kennedy, tariffs, Trump administration

Pfizer; Albert Bourla; Trump administration; Most Favored Nation (MFN) pricing; drug pricing; tariffs; pharmaceutical industry; direct-to-consumer (DTC) sales; policy negotiation; Robert F. Kennedy Jr.; Mehmet Oz; PhRMA

Trump Gives Pharma CEOs 60-Day Ultimatum for ‘Most Favored Nation’ Drug Pricing

2 months ago talkbio0Tagged Drug Industry, Drug Prescriptions, drug price, executive order, Health Policy, Medicaid, nation policy, Transplant Registry Unified Management Program

Trump; pharmaceutical industry; drug pricing; most favored nation policy; executive order; prescription drugs; healthcare policy; Medicaid; tariffs

FDA Seeks Greater Alignment Between CBER and CDER: Makary Informs Industry Leaders

2 months ago talkbio0Tagged Biological Factors, CBER, CDER, Cells, Drug Industry, gene therapy, George Tidmarsh, Makary, Marty, Prasad, regulatory harmonization, United States Food and Drug Administration

FDA; CBER; CDER; regulatory harmonization; Marty Makary; George Tidmarsh; Vinay Prasad; cell and gene therapy; biologics; pharmaceutical industry

Novo Nordisk Names Insider Maziar Mike Doustdar as New CEO Amid Growth Challenges

2 months ago talkbio0Tagged Appointments, CEO, Drug Industry, drug market, growth outlook, international operations, Leadership Change, Maziar Mike Doustdar, Nordisk, Obesity

Novo Nordisk; Maziar Mike Doustdar; CEO appointment; leadership change; pharmaceutical industry; growth outlook; obesity drug market; international operations